Cantor Fitzgerald Downgrades Salix Pharmaceuticals (SLXP) to Hold

Go back to Cantor Fitzgerald Downgrades Salix Pharmaceuticals (SLXP) to Hold

UBS Downgrades Salix Pharmaceuticals (SLXP) to Neutral

February 24, 2015 7:22 AM EST

UBS downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.

For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.

Shares of Salix Pharmaceuticals closed at $155.76 yesterday.

... More

Valeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B Deal

February 22, 2015 4:29 PM EST

Valeant Pharma (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies.

Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of... More

Valeant Pharma (VRX) Nears Deal for Salix Pharma (SLXP) - CNBC's Faber

February 20, 2015 9:46 AM EST

(Updated - February 20, 2015 9:55 AM EST)

Valeant Pharma (NYSE: VRX) is near a deal to acquire Salix Pharma (NASDAQ: SLXP), CNBC's David Faber reported Friday.

Notably, rumors of a Salix Pharm takeover have been around... More